Skip to content
Biodatica
Start free

Acerta Pharma BV

Columbus, Ohio

OncologyPhase I
Compare Sign in to watch

What changed

Phase I trial registered: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

6d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Momentum 78 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,027 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jan 31, 2018

    Chronic Lymphocytic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Acerta Pharma BV · A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    ClinicalTrials.gov · NCT03328273 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Apr 20, 2016

    Mantle Cell Lymphoma (MCL) · ACTIVE_NOT_RECRUITING · sponsor: Acerta Pharma BV · A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

    ClinicalTrials.gov · NCT02717624 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Aug 18, 2014

    Chronic Lymphocytic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Acerta Pharma BV · Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

    ClinicalTrials.gov · NCT02157324 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources